NeoGenomics Launches Immuno-Oncology Companion Diagnostic Test for Triple Negative Breast Cancer in Conjunction with FDA Approval for TECENTRIQ(R) Mar 11, 2019
NeoGenomics Reports Record Revenue of $76 Million with 17% Organic Revenue Growth in the Fourth Quarter Feb 19, 2019
NeoGenomics Schedules its Fourth Quarter and Fiscal Year 2018 Earnings Release for February 19, 2019 Jan 28, 2019
NeoGenomics Announces Pricing on Secondary Offering of Common Stock by Selling Stockholder Dec 12, 2018
QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs Nov 30, 2018
